Havana, August 3 (RHC)-- The 15 municipalities of Havana concluded the anti-SARS-CoV-2 vaccination with Abdala, an immunogen developed by the Center for Genetic Engineering and Biotechnology. The injectable has 92.28 percent (%) efficacy against symptomatic disease and 100 percent in preventing severe illness and death.

María Elena Soto Entenza, head of the Primary Health Care Department of the Ministry of Public Health, said that around 1,355,000 people had been immunized up to this Sunday.

After concluding this stage, the specialist pointed out that 57 centralized vaccination sites were set up to complete the doses of those who are still pending.

She explained that to go to these facilities, those interested should coordinate it beforehand with the family doctor, who will indicate the corresponding site according to their planning.

Despite having completed the vaccination, the doctor insisted that the immunization schedule is not achieved until 14 to 28 days after the last dose. The control of the disease also depends on compliance with the security measures and achieving a high percentage of vaccinated patients.